Garage Brain Science Co., Ltd.
Update：2026/01/30
Industries
Main Industry
Health Care
Main Product/Service
The company’s product pipeline is built upon its proprietary research published in high-impact journals like Nature Communications, targeting protein dysregulation associated with conditions such as Motor Neuron Disease (MND), Alzheimer’s disease, and Parkinson’s disease. GBS focuses on developing precision drug candidates that address the underlying mechanisms of prion-like protein aggregation, aiming to provide effective treatments for complex neurological disorders that currently lack successful therapeutic options.
Founded Year
1900
Unified Business No.
89172624
Status
Active
Number of Employees
8
Total Paid-in
Capital
17,536,700 (NT$)
Location of Company
Taiwan
, Taichung City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Garage Brain Science (GBS) is a pioneering biotech company founded by molecular biologists Dr. Hsian-Yu Chang and Dr. I-Fan Wang, focusing on basic research and the development of novel therapeutics for unmet medical needs. The company specializes in neurodegenerative disorders and has gained international recognition for its groundbreaking research on prion-like pathological proteins and liquid-liquid phase separation. GBS is dedicated to creating a future free from neurodegenerative diseases by translating scientific discoveries into impactful clinical solutions.
